Results of TS-1 combined multimodality therapy for squamous cell carcinoma of maxillary sinus

Fourteen patients with SCC of maxillary sinus were treated with TS-1 combined with multimodality therapy at the Department of Otolaryngology, Tenriyorozu Hospital between October 2003 and July 2014. The T classification was as follows: 1 with T1, 2 with T2, 5 with T3, and 6 with T4. Only one patient had lymph node metastasis with N2b, and no patient had distal metastasis. The treatment consisted of 50Gy/25fr preoperative or postoperative radiotherapy with concomitant administration of TS-1 at the reduced dose, and surgery. The timing of surgical treatment was modified after 2005. Four patients died from their disease and all the remaining surviving patients show no evidence of disease. The 3-year and 5-year disease-specific survival rates were 84.7% and 75.2%, and the 3-year and 5-year local control rates were 76.9% and 65.9%, respectively. As for adverse events, radiation-induced mucositis was conspicuous but there was no significant hematotoxicity. The standard dose of TS-1 may be tolerable and may improve the effectiveness of this therapy.